Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Food and Drug Administration Safety and Innovation Act of 2012 | Statement: [FDC Act, amendedBy, Food and Drug Administration Safety and Innovation Act of 2012]

Target entity: Food and Drug Administration Safety and Innovation Act of 2012
Context triple: [FDC Act, amendedBy, Food and Drug Administration Safety and Innovation Act of 2012]

• A. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• B. Food and Drug Administration Modernization Act of 1997
  The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
• C. 21st Century Cures Act
  The 21st Century Cures Act is a U.S. federal law enacted in 2016 that accelerates medical product development and innovation, expands funding for biomedical research and mental health services, and modernizes the regulation of drugs and medical devices.
• D. Biologics Price Competition and Innovation Act
  The Biologics Price Competition and Innovation Act is a U.S. law that created an abbreviated regulatory pathway for approval of biosimilar and interchangeable biological products to promote competition while balancing incentives for innovation.
• E. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: Food and Drug Administration Safety and Innovation Act of 2012
Triple: [FDC Act, amendedBy, Food and Drug Administration Safety and Innovation Act of 2012]

The Food and Drug Administration Safety and Innovation Act of 2012 is a U.S. federal law that reauthorized and expanded FDA user fee programs while enhancing the agency’s authority over drug and medical device safety, innovation, and supply chain oversight.

Target entity: Food and Drug Administration Safety and Innovation Act of 2012
Target entity description: The Food and Drug Administration Safety and Innovation Act of 2012 is a U.S. federal law that reauthorized and expanded FDA user fee programs while enhancing the agency’s authority over drug and medical device safety, innovation, and supply chain oversight.

• A. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• B. Food and Drug Administration Modernization Act of 1997
  The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
• C. 21st Century Cures Act
  The 21st Century Cures Act is a U.S. federal law enacted in 2016 that accelerates medical product development and innovation, expands funding for biomedical research and mental health services, and modernizes the regulation of drugs and medical devices.
• D. Biologics Price Competition and Innovation Act
  The Biologics Price Competition and Innovation Act is a U.S. law that created an abbreviated regulatory pathway for approval of biosimilar and interchangeable biological products to promote competition while balancing incentives for innovation.
• E. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• F. None of above. chosen